ArticleMolecular biology reports2026
Mitochondrial miRNA- miR-181c-5p and mitomiR-106a-5p levels as indicators in cardiovascular disease patients.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hsa_circ_0065149 mediates the ceRNA network pathway: Research on the mechanism regulating myasthenia gravis.Journal of molecular neuroscience : MN · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMitochondrial dysfunction is a key contributor to the pathophysiology of cardiovascular disease (CVD), one of the leading causes of morbidity and mortality worldwide. Mitochondria-associated microRNAs (mitomiRs) have emerged as critical regulators of mitochondrial homeostasis and cardiac function; however, their clinical utility as circulating biomarkers remains incompletely defined. This study aimed to evaluate the diagnostic potential of circulating hsa-miR-181c-5p and hsa-miR-106a-5p in patients with CVD and to assess their applicability as early, non-invasive biomarkers in an Iraqi cohort.
methodsIn this case–control study, plasma samples were obtained from 30 patients with clinically diagnosed cardiovascular disease and 30 age-matched healthy controls. Total RNA was extracted, followed by complementary DNA synthesis. Expression levels of hsa-miR-181c-5p and hsa-miR-106a-5p were quantified using reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR). Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis.
resultsPlasma levels of hsa-miR-181c-5p were significantly upregulated in CVD patients, exhibiting a three-fold increase compared with controls (p = 0.0001). Likewise, hsa-miR-106a-5p expression was elevated by approximately four-fold in the CVD group (p = 0.0008). ROC analysis demonstrated robust discriminatory power for both miRNAs, with an area under the curve (AUC) of 0.796 for hsa-miR-181c-5p (p = 0.0002) and 0.749 for hsa-miR-106a-5p (p = 0.0010).
conclusionsOur findings identify circulating hsa-miR-181c-5p and hsa-miR-106a-5p as promising mitomiR-based biomarkers for cardiovascular disease. Their significant upregulation and diagnostic accuracy support their potential role in early, non-invasive detection of CVD and highlight the clinical relevance of mitochondrial miRNA dysregulation in cardiovascular pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.